Exploring cellular and molecular networks in heart and brain diseases

Single Cell Sequencing and Multidimensional Omics Studies in Cardiovascular and Neurological Diseases

This study is trying to find out how certain cells and genes are linked to heart and brain diseases like atrial fibrillation and moyamoya disease to help develop better treatments.

Quick facts

• Study type: Observational
• Enrollment: 400 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Qianfoshan Hospital (Academic / other)
• Locations: 1 site (Jinan, Shandong)
• Trial ID: NCT06114095 on ClinicalTrials.gov

What this trial studies

This observational study utilizes single-cell sequencing and multidimensional omics technologies to investigate the complex cellular and molecular regulatory networks involved in cardiovascular and neurological diseases. It aims to identify specific cell types and gene expression patterns associated with conditions such as atrial fibrillation, carotid atherosclerosis, and moyamoya disease. By analyzing clinical data and biological samples from a cohort of patients and healthy controls, the study seeks to uncover new pathological mechanisms and potential diagnostic and therapeutic targets for these diseases.

Who should consider this trial

Good fit: Ideal candidates include individuals aged 18 to 75 with specific cardiovascular or neurological conditions such as atrial fibrillation, carotid atherosclerosis, or moyamoya disease.

Not a fit: Patients outside the age range of 18 to 75 or those without the specified cardiovascular or neurological conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this research could lead to new diagnostic methods and treatments for cardiovascular and neurological diseases.

How similar studies have performed: Other studies utilizing single-cell sequencing and omics technologies have shown promise in understanding complex diseases, suggesting potential for success in this novel approach.

Eligibility criteria

Inclusion criteria

1. Inclusion criteria for patients with valvular atrial fibrillation:

   Moderate or above mitral valve disease; The occurrence of atrial fibrillation was recorded by 12-lead electrocardiogram or 24-hour holter electrocardiogram. 3.18≤ Age ≤75 years old.
2. Inclusion criteria for disease control of valvular atrial fibrillation:

   No moderate or above mitral valve disease; No history of atrial fibrillation, 24-hour holter electrocardiogram did not record the occurrence of atrial fibrillation. 3.18≤ Age ≤75 years old.
3. Inclusion criteria for carotid atherosclerosis cases:

   Carotid atherosclerosis was confirmed by ultrasound, CTA and other imaging diagnosis. 2.18≤ Age ≤75 years old.
4. Inclusion criteria for carotid atherosclerosis control:

   The inclusion criteria for carotid atherosclerosis cases were met. The peripheral tissue of the vascular plaque was discarded in the same patient.
5. Inclusion criteria for moyamoya disease cases:

   Imaging diagnosis confirmed moyamoya disease; 2.18≤ Age ≤75 years old.
6. Moyamoya disease control inclusion criteria:

Imaging diagnosis confirmed no moyamoya disease; 2.18≤ Age ≤75 years old.

Exclusion criteria

1. Exclusion criteria for patients with valvular atrial fibrillation:

   Coronary heart disease, myocardial infarction, hyperthyroidism, severe hepatic and renal insufficiency, benign and malignant tumors, etc. Dilated cardiomyopathy, hypertrophic cardiomyopathy, congenital heart disease, heart failure and other non-valvular factors cause atrial fibrillation.
2. Exclusion criteria for control of valvular atrial fibrillation:

   Coronary heart disease, myocardial infarction, hyperthyroidism, severe hepatic and renal insufficiency, benign and malignant tumors, etc. Dilated cardiomyopathy, hypertrophic cardiomyopathy, congenital heart disease, heart failure, etc.
3. Exclusion criteria for carotid atherosclerosis cases:

   History of carotid vascular surgery or trauma
4. Exclusion criteria for carotid atherosclerosis control:

   No plaque margin tissue or marginal tissue injury was found in abandoned vessels in the same patient.
5. Exclusion criteria for moyamoya disease cases:

   Previous history of cerebrovascular surgery or trauma.
6. Exclusion criteria for moyamoya disease control:

Previous history of cerebrovascular surgery or trauma.

Where this trial is running

Jinan, Shandong

• The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital — Jinan, Shandong, China (Recruiting)

Study contacts

• Principal investigator: Xin Tao — The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
• Study coordinator: Xin Tao, Director of Neurosurgery

Conditions Nervous System Diseases; Cardiovascular Diseases